A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways.
ASAP1
EMT
FAK
HL142
Luminacin D analog
metastasis
ovarian tumor
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
03
2021
accepted:
07
07
2021
entrez:
18
8
2021
pubmed:
19
8
2021
medline:
19
8
2021
Statut:
epublish
Résumé
Epithelial to mesenchymal transition (EMT) is known to contribute to tumor metastasis and chemoresistance. Reversing EMT using small molecule inhibitors to target EMT associated gene expression represents an effective strategy for cancer treatment. The purpose of this study is to test whether a new luminacin D analog HL142 reverses EMT in ovarian cancer (OC) and has the therapeutic potential for OC. We chemically synthesized HL142 and tested its functions in OC cells
Identifiants
pubmed: 34405025
doi: 10.7150/jca.61066
pii: jcav12p5654
pmc: PMC8364639
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5654-5663Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
J Antibiot (Tokyo). 2000 Jun;53(6):579-90
pubmed: 10966073
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
Oncol Rep. 2017 Jun;37(6):3189-3200
pubmed: 28440503
Toxicol In Vitro. 2020 Dec;69:104973
pubmed: 32818624
Phys Biol. 2019 May 07;16(4):041004
pubmed: 30939460
Oncogene. 2001 Mar 8;20(10):1152-63
pubmed: 11313859
Anticancer Res. 2017 Mar;37(3):1313-1319
pubmed: 28314297
Mol Oncol. 2017 Jul;11(7):718-738
pubmed: 28590039
Sci Signal. 2014 Dec 02;7(354):rs7
pubmed: 25468996
Oncol Lett. 2020 Jul;20(1):974-980
pubmed: 32566028
J Cell Biochem. 2018 Apr;119(4):3373-3383
pubmed: 29130517
Front Oncol. 2019 Sep 10;9:887
pubmed: 31552191
Org Lett. 2004 Oct 28;6(22):3909-12
pubmed: 15496061
Tumour Biol. 2014 Jun;35(6):5953-63
pubmed: 24682952
Front Biosci (Landmark Ed). 2014 Jan 01;19:687-706
pubmed: 24389213
Oncogene. 2002 Mar 27;21(13):2037-50
pubmed: 11960376
J Cell Physiol. 2018 Apr;233(4):3207-3217
pubmed: 28834540
Oncotarget. 2016 Aug 23;7(34):55771-55788
pubmed: 27304054
Cells. 2020 Jun 26;9(6):
pubmed: 32604782
Oncogene. 2001 Apr 19;20(17):2068-79
pubmed: 11360191
Breast Cancer Res. 2012 Jan 19;14(1):202
pubmed: 22264257
Onco Targets Ther. 2019 Aug 08;12:6253-6265
pubmed: 31496729
Folia Med (Plovdiv). 2019 Jun 1;61(2):296-302
pubmed: 31301662
Oncogene. 2020 May;39(21):4227-4240
pubmed: 32284541
J Cancer Res Ther. 2019 Oct-Dec;15(6):1309-1315
pubmed: 31898665
Arch Toxicol. 2017 Feb;91(2):605-619
pubmed: 28032148
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1081-1088
pubmed: 29170132
FASEB J. 2014 Jul;28(7):2775-89
pubmed: 24668754
Mol Cell Biol. 1998 Dec;18(12):7038-51
pubmed: 9819391
Oncotarget. 2017 Oct 17;8(55):94666-94680
pubmed: 29212257
J Antibiot (Tokyo). 2000 Jun;53(6):591-6
pubmed: 10966074
Mol Cell Biol. 1999 Mar;19(3):2330-7
pubmed: 10022919
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861725
Int J Mol Sci. 2019 Jan 02;20(1):
pubmed: 30609691
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31213009
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
Histochem Cell Biol. 2020 Aug;154(2):215-230
pubmed: 32382787
J Cancer Sci Ther. 2015;7(2):34-43
pubmed: 26819680
Trends Cancer. 2020 Nov;6(11):942-950
pubmed: 32680650
J Cell Physiol. 2007 Dec;213(3):581-8
pubmed: 17708542
Curr Med Sci. 2018 Aug;38(4):590-596
pubmed: 30128866
Mol Biol Cell. 2002 Jun;13(6):2147-56
pubmed: 12058076
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7036-41
pubmed: 16636290
Sci Rep. 2015 Nov 09;5:16492
pubmed: 26549110
Mol Cell Biochem. 2010 Jul;340(1-2):21-9
pubmed: 20177740
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Mol Cancer Ther. 2019 Dec;18(12):2233-2245
pubmed: 31515295
Matrix Biol. 2010 Mar;29(2):135-42
pubmed: 19840848
Cancer Res. 2008 Jun 1;68(11):4352-9
pubmed: 18519696
PLoS One. 2013 Sep 04;8(9):e74342
pubmed: 24023938
Oncotarget. 2015 Mar 10;6(7):4757-72
pubmed: 25749031
Oncol Lett. 2018 Apr;15(4):4432-4438
pubmed: 29541211
Oncogene. 2017 Jun 15;36(24):3384-3396
pubmed: 28114283